Alpha 2.0
Login Register
» Authors » Joel Neutel

Joel Neutel

Explore the profile of Joel Neutel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 579
Followers 0
Related Specialties
Cardiology & Vascular Diseases
Pharmacology
Endocrinology
Top 10 Co-Authors
Yves Lacourciere
Dean J Kereiakes
Maximilian von Eynatten
Jay N Cohn
Odd Erik Johansen
Ali Shojaee
Marc A Pfeffer
Jennifer Hellawell
Gary F Mitchell
Miriam Kidron
Published In
J Clin Hypertens (Greenwich)
Circulation
Ther Adv Cardiovasc Dis
Diabetes Obes Metab
Metabolites
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction to: Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide to Oral and Intravenous Formulations
Ambrosy A, Bensimhon D, Bernstein G, Kolski B, Neutel J, Lala A, et al.
Circulation . 2025 Mar; 151(10):e708. PMID: 40063725
No abstract available.
2.
A Randomized, Placebo-Controlled, Single-Center, Crossover Study to Evaluate the Effects of Pre-Meal Whey Protein Microgel on Post-Prandial Glucometabolic and Amino Acid Response in People with Type 2 Diabetes and Overweight or Obesity
Neeland I, de Gregorio L, Zagury R, Ahren B, Neutel J, Darimont C, et al.
Metabolites . 2025 Jan; 15(1). PMID: 39852403
: Whey protein (WP) consumption prior to a meal curbs appetite and reduces postprandial glucose (PPG) through stimulating endogenous GLP-1 secretion and insulin. : We assessed the metabolic effects of...
3.
Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide With Oral and Intravenous Formulations
Ambrosy A, Bensimhon D, Bernstein G, Kolski B, Neutel J, Lala A, et al.
Circulation . 2024 Nov; 151(10):737-740. PMID: 39555978
No abstract available.
4.
Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People...
Johansen O, Neutel J, Gupta S, Mariani B, Ufheil G, Perrin E, et al.
Metabolites . 2024 Aug; 14(8). PMID: 39195506
We assessed the glucometabolic effects of oligomalt, a novel fully slowly digestible carbohydrate, compared with maltodextrin, in cross-over randomized controlled trials (NCT05058144; NCT05963594) involving healthy volunteers (HV), people with overweight...
5.
Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial
Ishay Y, Neutel J, Kolben Y, Gelman R, Arbib O, Lopez O, et al.
Gastro Hep Adv . 2024 Aug; 3(3):417-425. PMID: 39131144
Background And Aims: Metabolic dysfunction-associated steatohepatitis is an advanced form of nonalcoholic fatty liver disease and a leading cause of end-stage liver disease and transplantation. Insulin resistance and inflammation underlie...
6.
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Veniant M, Lu S, Atangan L, Komorowski R, Stanislaus S, Cheng Y, et al.
Nat Metab . 2024 Feb; 6(2):290-303. PMID: 38316982
Obesity is a major public health crisis. Multi-specific peptides have emerged as promising therapeutic strategies for clinical weight loss. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are endogenous incretins...
7.
A Randomized, Placebo-Controlled Crossover Study to Evaluate Postprandial Glucometabolic Effects of Mulberry Leaf Extract, Vitamin D, Chromium, and Fiber in People with Type 2 Diabetes
Mohamed M, Zagury R, Bhaskaran K, Neutel J, Nisak Mohd Yusof B, Mooney L, et al.
Diabetes Ther . 2023 Mar; 14(4):749-766. PMID: 36855010
Introduction: Reducing postprandial (PP) hyperglycemia and PP glucose excursions is important for overall glycemic management. Although most therapeutic lifestyle interventions that reduce caloric intake would affect this, there is no...
8.
Oral insulin (ORMD-0801) in type 2 diabetes mellitus: A dose-finding 12-week randomized placebo-controlled study
Eldor R, Francis B, Fleming A, Neutel J, Homer K, Kidron M, et al.
Diabetes Obes Metab . 2022 Oct; 25(4):943-952. PMID: 36281496
Aims: To assess the safety and efficacy of multiple daily doses of oral insulin (ORMD-0801) in subjects with type 2 diabetes (T2DM) over 12 weeks. Materials And Methods: Participants with...
9.
Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study
Sohn W, Winkle P, Neutel J, Wu Y, Jabari F, Terrio C, et al.
Clin Ther . 2022 Aug; 44(9):1237-1247. PMID: 35963802
Purpose: Olpasiran, an N-acetyl galactosamine-conjugated, hepatocyte-targeted, small interfering RNA, is being developed to reduce plasma lipoprotein (Lp)-(a) concentration by directly targeting the LPA gene. This study evaluated the pharmacokinetics, pharmacodynamics,...
10.
A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients
Winkle P, Goldsmith S, Koren M, Lepage S, Hellawell J, Trivedi A, et al.
Cardiovasc Drugs Ther . 2022 Apr; 37(4):743-755. PMID: 35460392
Purpose: AMG 986 is a novel apelin receptor (APJ) agonist that improves cardiac contractility in animal models without adversely impacting hemodynamics. This phase 1b study evaluated the safety/tolerability, pharmacokinetics, and...